• Consensus Rating: Moderate Buy
  • Consensus Price Target: $50.95
  • Forecasted Upside: 16.50%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$43.73
▲ +0.56 (1.30%)

This chart shows the closing price for QGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Qiagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QGEN

Analyst Price Target is $50.95
▲ +16.50% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Qiagen in the last 3 months. The average price target is $50.95, with a high forecast of $60.00 and a low forecast of $43.30. The average price target represents a 16.50% upside from the last price of $43.73.

This chart shows the closing price for QGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Qiagen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2024Stifel NicolausLower TargetHold ➝ Hold$55.00 ➝ $45.00Low
2/16/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$49.48 ➝ $51.00Low
2/8/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$50.00 ➝ $52.00Low
2/8/2024CitigroupLower TargetBuy ➝ Buy$61.86 ➝ $60.00Low
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$46.39 ➝ $51.55Low
12/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$45.36Low
12/13/2023Wolfe ResearchInitiated CoveragePeer PerformLow
12/7/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$51.55Low
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$49.48 ➝ $43.30Low
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$56.70 ➝ $51.55Low
9/29/2023HSBCLower Target$65.98 ➝ $58.76Low
9/26/2023CitigroupReiterated RatingBuy ➝ Buy$61.86Low
9/11/2023Robert W. BairdInitiated CoverageOutperform$51.55Low
8/9/2023UBS GroupLower TargetNeutral ➝ Neutral$51.55 ➝ $49.48Low
5/23/2023Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
5/5/2023UBS GroupLower Target$53.61 ➝ $51.55Low
2/9/2023UBS GroupBoost TargetNeutral$51.55 ➝ $53.61Low
2/9/2023CitigroupBoost TargetBuy$56.70 ➝ $61.86Low
11/11/2022Berenberg BankBoost Target€55.58 ➝ €56.29Low
11/9/2022CitigroupLower TargetBuy$63.92 ➝ $56.70Low
11/8/2022William BlairReiterated RatingMarket PerformLow
10/18/2022Morgan StanleyInitiated CoverageEqual WeightLow
10/10/2022Oddo BhfDowngradeOutperform ➝ NeutralLow
1/17/2022DZ BankUpgradeHold ➝ BuyLow
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight$59.79 ➝ $61.86High
11/26/2021Kepler Capital MarketsDowngradeHold$50.52High
10/21/2021Norddeutsche LandesbankReiterated RatingHoldLow
10/14/2021Redburn PartnersInitiated CoverageBuyLow
7/14/2021CheuvreuxDowngradeBuy ➝ Hold$51.06Medium
7/14/2021Kepler Capital MarketsDowngradeBuy ➝ Hold$51.06Medium
7/14/2021CitigroupLower TargetBuy$67.01 ➝ $59.79Medium
7/9/2021Kepler Capital MarketsUpgradeBuy$52.58High
6/25/2021DZ BankReiterated RatingNeutralLow
6/17/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
6/11/2021Berenberg BankReiterated RatingBuyLow
6/8/2021The Goldman Sachs GroupReiterated RatingBuyLow
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$53.61Low
5/4/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyMedium
4/22/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
4/7/2021DZ BankReiterated RatingNeutralMedium
4/2/2021Kepler Capital MarketsReiterated RatingBuyN/A
4/1/2021DZ BankReiterated RatingNeutralLow
2/19/2021Berenberg BankReiterated RatingBuyMedium
2/17/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
2/10/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
1/6/2021Norddeutsche LandesbankReiterated RatingHoldN/A
1/6/2021Nord/LBReiterated RatingNeutralN/A
12/14/2020DZ BankReiterated RatingSellLow
12/10/2020Exane BNP ParibasReiterated RatingOutperformHigh
12/9/2020Deutsche Bank AktiengesellschaftReiterated RatingBuyMedium
12/9/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
11/26/2020Kepler Capital MarketsUpgradeBuyLow
11/11/2020DZ BankReiterated RatingSellMedium
11/4/2020Berenberg BankReiterated RatingBuyLow
10/28/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
10/6/2020Bank of AmericaUpgradeNeutral ➝ Buy$60.82Medium
9/28/2020Kepler Capital MarketsUpgradeHold ➝ Buy$61.15Medium
9/15/2020DZ BankReiterated RatingNeutralLow
8/30/2020Kepler Capital MarketsUpgradeHoldLow
8/26/2020CommerzbankUpgradeHold ➝ Buy$68.04Low
8/24/2020CitigroupUpgradeNeutral ➝ Buy$49.48 ➝ $63.92Medium
8/20/2020JPMorgan Chase & Co.Reiterated RatingOverweight$61.86Low
8/17/2020Wolfe ResearchInitiated CoverageMarket Perform$60.82Low
8/17/2020Berenberg BankUpgradeHold ➝ BuyHigh
8/14/2020Exane BNP ParibasUpgradeNeutral ➝ OutperformHigh
8/14/2020BNP ParibasUpgradeNeutral ➝ OutperformMedium
8/14/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$32.99 ➝ $61.86High
7/20/2020DZ BankReiterated RatingNeutralLow
7/14/2020DZ BankReiterated RatingNeutralMedium
6/23/2020Warburg ResearchReiterated RatingHold ➝ NeutralLow
5/29/2020DZ BankReiterated RatingNeutralLow
5/6/2020Warburg ResearchReiterated RatingHoldLow
4/2/2020Stifel NicolausBoost TargetHold$34.02 ➝ $41.24Low
3/25/2020Kepler Capital MarketsReiterated RatingHoldLow
3/6/2020CfraBoost TargetHold$39.18 ➝ $43.30Low
3/4/2020Berenberg BankDowngradeBuy ➝ HoldMedium
3/3/2020DZ BankReiterated RatingNeutralLow
2/11/2020DZ BankReiterated RatingNeutralLow
2/6/2020CfraLower TargetHold$41.24 ➝ $39.18Medium
2/6/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
2/5/2020Piper SandlerBoost TargetNeutral$29.90 ➝ $37.11Medium
2/5/2020BarclaysReiterated RatingNeutralHigh
2/5/2020CommerzbankReiterated RatingNeutralMedium
1/10/2020UBS GroupLower TargetNeutral$40.21 ➝ $37.11Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$37.11Medium
1/6/2020CitigroupInitiated CoverageNeutral$36.08Low
1/6/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/6/2020CommerzbankDowngradeBuy ➝ HoldLow
1/2/2020DZ BankReiterated RatingNeutralLow
12/27/2019DZ BankReiterated RatingNeutralLow
12/26/2019UBS GroupReiterated RatingHold$40.21Medium
12/26/2019Bank of AmericaReiterated RatingUnderperform$28.87High
11/27/2019CommerzbankUpgradeHold ➝ BuyLow
11/22/2019DZ BankReiterated RatingBuyLow
11/18/2019CommerzbankUpgradeHold ➝ Buy$49.48Medium
11/14/2019Stifel NicolausInitiated CoverageHold$34.02High
11/14/2019DZ BankReiterated RatingBuyLow
11/14/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/14/2019Kepler Capital MarketsUpgradeReduce ➝ HoldHigh
11/14/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$25.77 ➝ $41.24High
10/17/2019Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
10/9/2019UBS GroupReiterated RatingNeutralHigh
10/9/2019Kepler Capital MarketsDowngradeHold ➝ ReduceHigh
10/8/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldHigh
10/8/2019Bank of AmericaLower TargetNeutral$41.24 ➝ $34.02High
10/8/2019BarclaysDowngradeOverweight ➝ Equal Weight$32.99High
10/8/2019Piper Sandler CompaniesLower TargetNeutral$37.11 ➝ $31.96High
10/8/2019JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$39.18 ➝ $25.77High
10/1/2019Berenberg BankReiterated RatingBuyHigh
8/1/2019The Goldman Sachs GroupReiterated RatingBuyLow
7/26/2019Berenberg BankReiterated RatingBuy$41.24Low
7/26/2019Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
7/24/2019DZ BankReiterated RatingNeutralLow
7/12/2019Exane BNP ParibasUpgradeNeutral ➝ OutperformLow
7/12/2019BNP ParibasUpgradeNeutral ➝ OutperformLow
6/21/2019BarclaysBoost TargetOverweight$44.33 ➝ $46.39Low
6/21/2019The Goldman Sachs GroupReiterated RatingBuyLow
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 4 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2023
  • 11 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 11 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/29/2024
  • 10 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/28/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/29/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/28/2024
  • 17 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 17 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Qiagen logo
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Read More

Today's Range

Now: $43.73
Low: $43.55
High: $43.85

50 Day Range

MA: $42.61
Low: $39.23
High: $45.99

52 Week Range

Now: $43.73
Low: $34.74
High: $47.70

Volume

614,100 shs

Average Volume

1,257,294 shs

Market Capitalization

$9.98 billion

P/E Ratio

29.32

Dividend Yield

N/A

Beta

0.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Qiagen?

The following Wall Street analysts have issued reports on Qiagen in the last year: Citigroup Inc., HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Stifel Nicolaus, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for QGEN.

What is the current price target for Qiagen?

9 Wall Street analysts have set twelve-month price targets for Qiagen in the last year. Their average twelve-month price target is $50.95, suggesting a possible upside of 16.5%. Citigroup Inc. has the highest price target set, predicting QGEN will reach $60.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $43.30 for Qiagen in the next year.
View the latest price targets for QGEN.

What is the current consensus analyst rating for Qiagen?

Qiagen currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for QGEN.

What other companies compete with Qiagen?

Other companies that are similar to Qiagen include Biogen, BioNTech, argenx, Neurocrine Biosciences and Bio-Techne. Learn More about companies similar to Qiagen.

How do I contact Qiagen's investor relations team?

Qiagen's physical mailing address is HULSTERWEG 82, VENLO P7, 5912. The company's listed phone number is (177) 355-6600 and its investor relations email address is [email protected]. The official website for Qiagen is www.qiagen.com. Learn More about contacing Qiagen investor relations.